IRLAB Therapeutics: mesdopetam rör sig framåt i planeringsskedet

Research Note

2020-06-05

08:20

Igår publicerade Irlab Therapeutics (Irlab) mer information kring kommande fas IIb/III studie med mesdopetam i PD-LIDs, vilket Redeye ger sin syn på i denna kommentar.

AH

Anders Hedlund

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.